Biogen has bagged $250 million to advance a key pipeline prospect. Royalty Pharma is providing the cash to bankroll phase 3 development of a lupus candidate that Biogen has named in a bunch of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback